Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Detection of Extracochlear Electrodes Using Electrical Field Imaging (EFI)
Saoji, Aniket A. , Staricha, Kelly L. , DeJong, Melissa D., Dornhoffer, James R. , Neff, Brian A., Driscoll, Colin L. W., Koka, Kanthaiah , Lane, John I. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | January 10, 2025 | Volume: 46 | Issue: 2 | Pages: e51-e55

10.1097/mao.0000000000004390 | PMID 39792979 Get It

Objective To analyze the use of electrical field imaging (EFI) in the detection of extracochlear electrodes in cochlear implants (CI) Study Design Retrospective cohort study Setting Tertiary academic medical center Methods EFI patterns from 6 recipients with extracochlear electrodes were compared with 10 recipients with all intracochlear electrodes to identify differences in EFI patterns between these two groups. For the extracochlear group, EFI patterns were analyzed using two methods: visual inspection and calculation of the average impedance difference (AID) between specific EFI curves. These results were then compared with information from CT and plain film imaging, surgical notes, and audiology tests to confirm the placement of the electrodes in each recipient. Results An average AID of 0.06 kΩ was calculated from the EFI patterns for recipients with complete electrode insertion, whereas an average AID of 0.15 kΩ was calculated from the EFI curves measured for the extracochlear electrodes. Visual analysis of the EFI impedance curves for extracochlear electrodes showed a distinct separation from those measured for intracochlear electrodes. Based on AID analysis and visual inspection the EFI, patterns were in close agreement with the number of extracochlear electrodes detected based on either imaging, intraoperative surgical note, or audiological findings. Conclusion EFI is a noninvasive, inexpensive, and time-efficient measurement that can be used to detect extracochlear electrodes and monitor electrode migration from the cochlea.
Shared ligand-blocking mechanism but distinct conformational modulation by α5-targeting antibodies BIIG2 and MINT1526A
Nguyen, Adam , Cordara, Gabriele , Chan, Matthew C. , Johannesen, Hedda , Charlesworth, M. Cristine , Azumaya, Caleigh M. , Madden, Benjamin , Krengel, Ute , Meves, Alexander , Heim, Joel B , Cordara, Gabriele , Chan, Matthew C , Johannesen, Hedda , Charlesworth, Cristine, Azumaya, Caleigh M , Madden, Benjamin , Krengel, Ute , Meves, Alexander , Campbell, Melody G , Heim, Joel B. , Li, Ming , Campbell, Melody G.

Mayo Clinic

No container title available | January 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.08.631572 | PMID 39829743 Get It

Summary Integrins are heterodimeric receptors important for cell adhesion and signaling. Integrin α5β1 is a key mediator of angiogenesis and its dysregulation is associated with tumor progression and metastasis. Despite numerous efforts, α5β1-targeting therapeutics have been unsuccessful due to poor efficacy and off-target effects. A contributing factor is our limited understanding of how integrin conformation influences interactions with therapeutics. Using cell-based functional assays, patient-derived xenografts, biophysics, and electron microscopy, we shed light on these relationships by characterizing two anti-α5β1 antibodies, BIIG2 and MINT1526A. We show that both antibodies bind α5β1 with nanomolar affinity, reduce tube formation in vitro , and bind overlapping epitopes that block fibronectin binding. However, using electron microscopy, we reveal that while BIIG2 binding does not substantially alter the conformational states, MINT1526A preferentially recognizes the bent conformation and restricts the conformational ensemble. These insights can guide which aspects to prioritize to improve the design of future integrin-targeted therapeutics.
Atrial Fibrillation and Retinal Stroke
Lusk, Jay B. , Dumitrașcu, Oana , Poli, Sven , Piccini, Jonathan P. , Fan, Li , O’Brien, Emily C. , Grory, Brian Mac , Poli, Sven , Mac Grory, Brian , Nalawade, Vinit V. , Wilson, Lauren E. , Song, Ailin , Schrag, Matthew , Biousse, Valérie , Hammill, Bradley G. , Xian, Ying

Mayo Clinic

JAMA Network Open | January 9, 2025 | Volume: 8 | Issue: 1 | Pages: e2453819

10.1001/jamanetworkopen.2024.53819 | PMID 39786774 Get It

ImportanceAtrial fibrillation (AF) is the most common, chronic, cardiac arrythmia in older US adults. It is not known whether AF is independently associated with increased risk of retinal stroke (central retinal artery occlusion), a subtype of ischemic stroke that causes severely disabling visual loss in most cases and is a harbinger of further vascular events.ObjectiveTo determine whether there is an association between AF and retinal stroke.Design, Setting, and ParticipantsThis retrospective cohort study was performed between July 2023 and May 2024 using computerized inpatient, outpatient, emergency department, and skilled nursing facility claims files for a 5% sample of US fee-for-service Medicare beneficiaries aged 66 years and older between 2000 and 2020. Follow-up ended at death, conclusion of fee-for-service Medicare coverage, end of the study period, or loss to follow-up of 85% of the study cohort.ExposureAF, based on validated International Classification of Diseases, Ninth Revision, Clinical Modification and International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes.Main Outcomes and MeasuresThe primary end point was incident retinal stroke in the primary diagnostic position of a single claim in any venue of care. Secondary end points included retinal stroke in any position of a single claim, 1 positive control end point (cerebral ischemic stroke), and 4 negative control end points (central retinal vein occlusion, urinary tract infection, humeral fracture, and cataract). Unadjusted and adjusted hazard ratios (HRs) and rate differences were computed across matched and overlap-weighted cohorts with and without AF (defined as 1 inpatient claim or 2 outpatient claims within a 365-day period).ResultsIn total, 1 090 144 patients (591 400 female [54.3%]; mean [SD] age, 76.92 [7.09] years) were included in the study; 545 072 patients had AF and 545 072 were matched controls. The median (IQR) follow-up was 45 (18 to 90) months. In total, 1333 patients with AF (rate, 0.55 per 1000 person-years) and 1082 AF-free matched controls (rate, 0.50 per 1000 person-years) experienced retinal stroke. The cause-specific, adjusted HR of retinal stroke after overlap weighting was 1.14 (95% CI, 1.02 to 1.28; adjusted rate difference, 0.05 [95% CI, −0.01 to 0.11]). AF was associated with cerebral ischemic stroke (adjusted HR, 1.73 [95% CI, 1.69 to 1.76]; adjusted rate difference, 10.11 [95% CI, 9.72 to 10.49]). Of 4 prespecified negative control end points, AF was not associated with central retinal vein occlusion but was associated with urinary tract infection, cataract, and humeral fracture.Conclusions and RelevanceIn this cohort study of Medicare beneficiaries aged 66 years and older, AF was independently associated with retinal stroke. The magnitude of the association was small, and a contribution from residual, unmeasured confounding could not be excluded.
Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting
Bennedsen, Tine Litske , Simonsen, Mikkel Runason , Jensen, Paw , Josefsson, Pär, Khurana, Arushi , Clausen, Michael Roost , Dessau‐Arp, Andriette, Jørgensen, Jennifer Bøgh , Jørgensen, Judit , Larsen, Thomas Stauffer , Pedersen, Lars Møller , Jakobsen, Lasse Hjort , Joergensen, Judit Mészáros , Clausen, Michael Roost , Pedersen, Lars Møller , Jensen, Paw , Brown, Peter de Nully , Maurer, Matthew J. , El‐Galaly, Tarec Christoffer

Mayo Clinic

European Journal of Haematology | January 9, 2025 | Volume: 114 | Issue: 5 | Pages: 832-839

10.1111/ejh.14373 | PMID 39786332 Get It

ABSTRACTThe development of new first‐line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients with FL who underwent contemporary first‐line therapies but would not have been eligible for inclusion in recent trials and explored how commonly used in/exclusion criteria impacted their survival outcomes. This study included adult patients diagnosed with FL in the period 2000–2018 registered in the Danish Lymphoma Registry. Through searches on ClinicalTrials.gov, four recent 1st line phase 3 randomized controlled trials with R‐Bendamustine, R‐CVP, and/or R‐CHOP as control or experimental arms were included. Inclusion and exclusion criteria for each trial were retrieved and categorized. Patients were then divided into trial‐eligible and ineligible groups according to blood test results correlated to organ function and ECOG performance score (PS). Survival outcomes were significantly worse among trial‐ineligible patients, with adjusted differences between trial‐eligible and ineligible patients of 12%–20% in five‐year overall survival (OS) overall. Inclusion criteria based on PS and renal function were the main drivers of OS differences. More inclusive trials will lead to faster recruitment and secure focus on developing medicines for the group of patients with the worst outcomes.
Implementation and Validation of Face De‐Identification (de‐facing) in ADNI‐4
Schwarz, Christopher G., Choe, Mark, Rossi, Stéphanie, Ittyerah, Ranjit, Fletcher, Evan, Singh, Baljeet , Malone, Ian B., Prosser, Lloyd , Matoush, Leonard, Ward, Chadwick P., Prakaashana, Carl M., DeCarli, Charles , Initiative, The Alzheimer's Disease Neuroimaging, Malone, Ian B. , Schwarz, Christopher G. , Tosun, Duygu , Yushkevich, Paul A. , Rossi, Stephanie, Das, Sandhitsu R. , Maillard, Pauline , Harvey, Danielle , Senjem, Matthew L. , Barkhof, Frederik , Jack, Clifford R. , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.085266 Get It

AbstractBackgroundRecent advances in automatic face recognition have increased the risk that de‐identified research imaging data could be re‐identified from face imagery in brain scans.MethodAn ADNI committee of independent imaging experts evaluated 11 published techniques for face‐deidentification (“de‐facing”) and selected four algorithms (FSL‐UK Biobank, HCP/XNAT, mri_reface, and BIC) for formal testing using 183 longitudinal scans of 61 racially and ethnically diverse ADNI participants, evaluated by their facial feature removal on 3D rendered surfaces (confirming sufficient privacy protection) and by comparing measurements from ADNI routine image analyses on unmodified vs. de‐faced images (confirming negligible side effects on analyses).ResultEffects of the de‐facing methods on FreeSurfer at UCSF (Figure 1‐top), ASHS at University of Pennsylvania (Figure 1 bottom‐left), and longitudinal atrophy at Mayo Clinic (Figure 1 bottom‐right) were comparable with each other and sufficiently small vs. unmodified scans to recommend de‐facing in ADNI‐4. The FSL and mri_reface methods were more thorough in removing facial features, partly because these also removed ears (Figure 2‐top). mri_reface was recommended for ADNI‐4 primarily because fewer (zero) images had modified brain (Figure 2‐bottom), and ADNI leadership approved de‐facing with mri_reface. ADNI performed a second validation of its latest version on another diverse sample of 100 ADNI‐3 participants. These analyses included: boundary shift interval at University College London, where average differences in measurements were all <0.05%; cortical white matter hyperintensities at UC Davis, where they found “minimum impact” (R>0.97); and others.ConclusionADNI‐4 de‐faces all indicated image types (Table 1) before subsequent pre‐processing, analyses, and public release. Sites upload images to the central repository (LONI), where they are queued to the MRI Core at Mayo Clinic for de‐facing. Image types requiring de‐facing are de‐faced using mri_reface. Trained analysts inspect de‐faced images to confirm complete removal of the face and complete non‐modification of the brain, and any flagged images are re‐processed manually until issues are resolved. De‐faced images are converted back to DICOM and re‐uploaded for further distribution. Image types not requiring de‐facing are indicated to proceed directly to subsequent steps. In summary, ADNI‐4 has adopted mri_reface because it successfully de‐faces without substantially affecting brain measurements.
Substantia nigra iron deposition in Lewy body disease: an MRI quantitative susceptibility mapping and neuropathology study
Przybelski, Scott A. , Lesnick, Timothy G. , Reichard, Ross R., Ono, Daisuke , Gunter, Jeffrey L. , Lowe, Val J. , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Petersen, Ronald C. , Diaz‐Galvan, Patricia , Nguyen, Aivi T. , Murray, Melissa E. , Dickson, Dennis W. , Schwarz, Christopher G. , Senjem, Matthew L. , Ramanan, Vijay K. , Jones, David T. , Botha, Hugo , Louis, Erik K. St. , Knopman, David S. , Day, Gregory S. , Jack, Clifford R. , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091491 Get It

AbstractBackgroundParkinson’s disease and dementia with Lewy bodies are characterized by abnormal iron deposition in the substantia nigra, which can be measured with quantitative susceptibility mapping (QSM) on MRI. However, neuropathologic validation of the increased QSM in the substantia nigra associated with Lewy body disease (LBD) is lacking. We compared substantia nigra QSM on antemortem MRI between patients with and without Lewy‐related pathology which was confirmed by autopsy in all cases.MethodWe studied cases with antemortem QSM who underwent autopsy from the Mayo Clinic Alzheimer’s Disease Research Center and Mayo Clinic Study of Aging (n=54). Immunohistochemistry was performed with rabbit NACP antibody against the amino acids 98‐115 of the α‐synuclein protein to detect Lewy‐related pathology. After neuropathologic evaluation, cases were classified as LBD‐present (n=13) if they had Lewy‐related pathology and LBD‐absent (n=42) if they did not have Lewy‐related pathology. Alzheimer’s disease co‐pathology was present in 9 of the LBD‐present cohort (70%). QSM was calculated for the whole substantia nigra and the two sub‐regions: pars compacta and pars reticulata. Non‐parametric Wilcoxon rank‐sum test was used to compare substantia nigra QSM values between LBD‐present and LBD‐absent cases. Area under the curve (AUC) analyses tested the accuracy of QSM to distinguish the two groups.ResultsLBD‐present group had higher QSM values in the substantia nigra than LBD‐absent group. Furthermore, sub‐regional analyses showed that the LBD‐present group had higher QSM in the substantia nigra pars compacta (p=0.008) but not in the pars reticulata than the LBD‐absent group (Figure 1). QSM of the substantia nigra pars compacta distinguished LBD‐present and LBD‐absent cases with good accuracy (AUC=0.74; p=0.006; Figure 2).ConclusionThis study provides neuropathologic insight into the relevance of QSM of substantia nigra pars compacta as an in‐vivo biomarker of autopsy‐confirmed LBD. These findings indicate that imaging evidence of abnormal iron deposition in the substantia nigra may serve as a biomarker of Lewy‐related pathology in patients with primary LBD (i.e., Parkinson disease, dementia with Lewy bodies) and patients with potential LBD co‐pathology (e.g., patients with Alzheimer disease).
Measuring the Potential Risk of Re‐identification of Imaging Research Participants from Open‐Source Automated Face Recognition Software
Prakaashana, Carl M., Savvides, Marios , Gunter, Jeffrey L. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Senjem, Matthew L. , Vemuri, Prashanthi , Kantarci, Kejal , Graff‐Radford, Jonathan , Knopman, David S. , Jack, Clifford R. , Schwarz, Christopher G.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091462 Get It

AbstractBackgroundResearch subjects can potentially be re‐identified from de‐identified MRI, CT, and PET brain scans with up to 98% accuracy using Microsoft Azure’s cloud‐based commercial facial recognition software. This showed the need to “de‐face” publicly shared research brain scans. Subsequently, Microsoft has begun restricting its face recognition services, intending to prevent misuse. This study tests a variety of popular open‐source computer vision and facial recognition software packages to measure the re‐identification risk with only unrestricted free software.MethodThis study used brain MRI from Siemens 3T scanners and face photographs from 182 participants (ages 30‐90+) in the Mayo Clinic Study of Aging. Each participant had photos taken with an iPad, which were cropped loosely around the head and converted to black and white. A total of 81 renders (2D reconstruction images; Figure 1) were made from each 3D T2‐FLAIR MRI, simulating various camera and lighting positions. These face renders approximate black and white photos, allowing use with software packages developed for matching faces/features between photographs.Open‐source Python packages (OpenCV, DeepFace, face_recognition, scikit‐learn) and their included pre‐trained models (designed for photographs) were used to match participant photographs to the labelled library of MRI‐based face renders. A correct match was recorded when the top‐scoring render or set of renders automatically chosen by the algorithm was from the MRI of the correct participant.ResultFeature matching with ORB and SWIFT (both from OpenCV) produced no correct matches, despite a prior publication reporting moderate success. The best match rates (Figure 2) were 58‐59% accuracy using face_recognition or DeepFace packages with support vector machines (SVMs). Without SVMs, these packages performed modestly worse (51%‐55%).ConclusionWhile the highest match rates obtained by widely available open‐source packages (roughly 60%) are much lower than those of a limited‐access commercial product (Microsoft Azure, with 98%), they show that actors with only access to no‐cost readily available software could still re‐identify a research subject from a brain scan most of the time. This further highlights the need for image refacing software, such as mri_reface, to protect the privacy and identifies of research volunteers.
Increase in white matter hyperintensities in long‐COVID depends on age and hospitalization during acute SARS‐CoV‐2
Atık, Merve, Kendall‐Thomas, June, Przybelski, Scott A. , Kantarci, Orhun H. , Toledano, Michel , Fought, Angela J. , Lesnick, Timothy G. , Gundry, Katie, Lorente, Alfredo, Thotland, Jeromy, Li, Xiufeng , Manousakis, Georgios , Metzler, Abby, Byrne, Keenan, Juttukonda, Meher R. , Salat, David H. , Sherman, Janet C. , Pollak, Lauren, Nabi, Mehreen, Rehman, Sana , Karmonik, Christof , Gillani, Syed A , Flores, Vanesa, Davis, Rachel, Ashizawa, Tetsuo , Ratai, Eva, Kantarci, Kejal, Harrold, G. Kyle , Zeydan, Burcu , Senjem, Matthew L. , Schwarz, Christopher G. , Silva, Ana Isabel , Joers, James M. , Lorente, Alfredo, Deelchand, Dinesh K. , Park, Young Woo , Lenglet, Christophe , Eberly, Lynn E. , Mukerji, Shibani S. , Yaşar, Sevil , Öz, Gülin , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090998 Get It

AbstractBackgroundApproximately 10% of patients with acute SARS‐CoV‐2 infection present with persistent symptoms recognized as the long‐COVID. Neurological and cognitive symptoms are prevalent in long‐COVID, requiring a deeper understanding of the biological basis of this condition for potential therapeutic interventions. Cerebrovascular complications are observed during acute infection, underscoring the importance of understanding cerebrovascular outcomes. Our objective was to investigate white matter hyperintensities (WMH) as a potential indicator of microvascular disease associated with long‐COVID in the brainMethodParticipants with long‐COVID (n=71; hospitalized, n=9, non‐hospitalized, n=62 during the acute infection) and controls (n=50) who did not have a reported infection were recruited from the community at five US sites that participated in the COVID‐Brain‐Advanced‐Imaging‐Network (COVID‐BRAIN) project. To be included, participants with long‐COVID had to experience neurological or cognitive sequelae within 6 months after a confirmed infection and continued to show at least one neurological symptom. Clinical evaluation and MRI were performed an average of 20±10 months after the acute infection. WMH volumes were measured from the 3D T2‐weighted FLAIR MRIs using a semi‐automated approach for the WMH segmentation. A linear regression model predicting log transformed WMH volume was used to investigate the association of age, groups (hospitalized long‐COVID, non‐hospitalized long‐COVID, controls), and the interaction of these two predictors along with an adjustment for total intracranial volume. Additionally, predicted regression lines have been plotted on the untransformed WMH scale.ResultWe observed a greater age‐dependent increase in WMH volumes in the hospitalized patients with long‐COVID compared to the control group (group*age interaction, p=0.005). We did not observe this difference in slopes in the non‐hospitalized patients with long‐COVID compared to the controls. Figure shows the slopes of WMH volume as a percentage of the total intracranial volume by age in the three groups.ConclusionOur preliminary observation in this ongoing long‐Covid study suggests that hospitalization during acute COVID is associated with the age‐dependent increase in microvascular injury in the white matter. Older adults with acute infection that require hospitalization are more susceptible to cerebrovascular adverse outcomes than controls or those who do not require hospitalization. Impact of such microvascular changes on cognitive outcomes and persistence of post‐COVID symptoms is yet to be studied.
Blood‐based biomarkers of systemic inflammation, metabolic function, and vascular injury are elevated in patients with rapid progressive neurodegenerative disease
Satyadev, Nihal , Piura, Yoav , Graff‐Radford, Neill R. , Kuchenbecker, Lindsey A. , Tipton, Philip W. , Brier, Matthew R. , Dunham, Steven , O’Bryant, Sid E. , Day, Gregory S.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090378 Get It

AbstractBackgroundPatients with rapid progressive Alzheimer disease and related dementias (rpAD/ADRD) develop dementia within 1 year or incapacitation within 2 years of symptom onset. We previously showed that selected CSF biomarkers of neuronal injury (NfL, VILIP‐1), AD neuropathology (p‐tau181), and neuroinflammation (GFAP, MCP‐1, sTREM2) measured at presentation associated with etiologic diagnoses and reliably differentiated patients with treatment‐responsive causes of rapid progressive dementia. However, no differences were identified between CSF biomarkers in patients with rapid and typical progressive forms of AD/ADRD, leaving key questions unanswered concerning the mechanisms that drive rpAD/ADRD. Blood‐based biomarkers may inform the systemic factors that contribute to rpAD/ADRD, including the systemic inflammation, metabolic function, and vascular injury.MethodsBiomarkers of systemic inflammation (Eotaxin‐3, IFN‐γ, IL‐1b, IL‐2, IL‐4, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, TARC, TNF‐α), metabolic function (A2M, B2M, FABP‐3, FVII, I‐309, IL‐18, PPY, TNC, TPO), and vascular injury (CRP, SAA, sICAM‐1, sVCAM‐1) were measured in plasma obtained at presentation from patients with rpAD/ADRD (n=29) and age‐ and sex‐ similar participants with typical progressive AD/ADRD (n=39) enrolled in prospective studies of memory and aging at Mayo Clinic in Florida. Biomarker measures were completed at the University of North Texas Institute for Translational Research using Meso Scale Discovery multiplexed assays. Biomarker concentrations were compared between groups using univariate analyses; potential predictors (p<0.05) were further evaluated via step‐wise multivariate logistic regression.ResultsMarkers of vascular injury (SAA, CRP, sICAM‐1), metabolic function (I‐309, TPO), and systemic inflammation (Eotaxin‐3, TARC, TNF‐α) were increased in patients with rapid versus typical progressive AD/ADRD (p<0.05). Eotaxin‐3, I‐309, and SAA were independently associated with rpAD/ADRD in multivariable model after controlling for age and sex. The overall model correctly characterized 86.8% of patients, with an area under the curve of 0.864 (95%CI: 0.777‐0.950; p<0.001).ConclusionBlood‐based biomarkers of systemic inflammation, metabolic function, and vascular injury were elevated at presentation in patients with rapid vs typical AD/ADRD. These findings may provide additional insights into the mechanisms that drive rpAD/ADRD. Longitudinal measures from larger cohorts are needed to decipher the relationship between candidate biomarkers and rpAD/ADRD.
Modeling the temporal evolution of mass spectrometry plasma biomarkers
Therneau, Terry M. , Griswold, Michael E., Graff‐Radford, Jonathan, Lowe, Val J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Cogswell, Petrice M. , Lundt, Emily S. , Graff‐Radford, Jonathan , Algeciras‐Schimnich, Alicia , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S. , Vemuri, Prashanthi , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090361 Get It

AbstractBackgroundPlasma Aβ42/40 and p‐tau217 can predict amyloid positivity in cross‐sectional studies. However, it is unclear how plasma biomarkers perform longitudinally, which is important to inform their utility in tracking disease progression. The goal of this study is to describe temporal evolutions of plasma Aβ42/40 and ptau217 ratio (p‐tau217r) measured via mass spectrometry, p‐tau217 measured via an immunoassay, and amyloid PET.MethodsWe included participants in the Mayo Clinic Study of Aging with amyloid PET (PiB) and plasma Aβ42/40 + ptau217r (mass spectrometry, C2N) and/or p‐tau217 (Lilly, MSD). We fit a joint non‐linear mixed effects model with Aβ42/40, p‐tau217r, p‐tau217 (Lilly), and amyloid PET as outcomes and age, sex, APOE ε4 carriership and education as covariates. The model included a per‐participant adjustment (time‐shift) for each biomarker indicating how much earlier or later in time the biomarker was estimated to progress relative to the average participant, a correlation (R) between adjustments for each pair of biomarkers, and the impact of covariates on each biomarker’s timing.ResultsThe study included 1459 participants, age 77 (10) years, 44% female, 82% cognitively unimpaired. Mean (SD) years of followup was 5.6(3.0) years for mass spectrometry plasma measures, 2.5(0.7) years for p‐tau217 (Lilly), and 4.6(3.3) for amyloid PET. Model fits are shown for each biomarker, with greater variability in serial measurements for plasma than PET (Figure 1). Individual adjustments between each of the plasma biomarkers and amyloid PET were highly correlated: p‐tau217r, R=0.73 (95%CI: 0.67, 0.78); p‐tau217 (Lilly), R=0.66 (0.62, 0.7); Aβ42/40, R=0.6 (0.52, 0.68) (Figure 2). The p‐tau217r and Aβ42/40 individual adjustments were modestly correlated, R=0.39 (0.28, 0.49). APOE ε4 carriership had the strongest covariate effect on all biomarkers, e.g. p‐tau217r progression 9.4 (6.7, 12) years earlier (Figure 3).ConclusionsPlasma Aβ42/40 and p‐tau217 measured with currently available assays may both be amenable to longitudinal modeling, although the degree of variability in Aβ42/40 over time may pose challenges. Findings suggest that both plasma Aβ42/40 and p‐tau217r may provide information regarding an individual’s timing of progression on amyloid PET; lower correlations with each other than amyloid PET suggests that each analyte may provide complimentary information.